1-12 of 61062 Business Insights
Infectious disease research requires the ability to study the progression of infection and effects of treatment in realistic time frames. BacteriSense Fluorescent Pre-clinical Imaging Agent is a fast-clearing, targeted probe which binds to negatively charged lipids on the bacterial cell membrane, enabling the monitoring of infection progression in vivo non-invasively and in real time. Because the half-life of BacteriSense in vivo is as short as 45,minutes, image data can be acquired every day to track bacterial load during infection.
GSP®, is the new, automated neonatal screening system from ,PerkinElmer. It has multi-technology capability, which means ,that both DELFIA®, and prompt fluorescence assays can now be ,run on a common platform. Its versatility and speed help it to ,accommodate present and future screening needs.
Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense detects the tumor cell surface expression of carbonic,anhydrase 9 (CA IX) protein, which increases in hypoxic regions,within many tumors, especially in cervical, colorectal, non-small,cell lung tumors. Pairing HypoxiSense with optical fluorescent,imaging technology allows you to image and quantitate tumor,sub-regions undergoing hypoxia-related changes, non-invasively,and in vivo.
1-12 of 100029 Products & Services
Choose the Frontier™ range of Fourier Transform IR spectrometers for superior spectroscopic performance in demanding applications. Powerful and adaptable, the Frontier meets all your current analysis needs and can be expanded as your research goals evolve. An exceptional signal-to-noise ratio and photometric performance assures optimal spectral quality to ensure best-in-class sensitivity. This configurable platform provides dependable and consistent operation through years of service.